Revenue growth is driven by the Melinta acquisition and DefenCath expansion, but Q2 revenue ($101.9M) declined sequentially from Q1 ($127.4M) due to a non-recurring $9M sales allowance adjustment in Q1. The raised EBITDA guidance and new LDO contract are positive, but the sequential revenue drop and pending TDAPA expiration warrant monitoring. Watch for REZZAYO sNDA submission in Q3 and the LDO pilot start.
Drugs in focus
CRMD drug pipeline →rezafungin
▲ Bullish Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already marketed (approved March 2023). The supplemental indication for prophylaxis has a PDUFA target in Q1 2027, with a promotional launch targeted for H2 2027 if approved.
- Next catalyst
- NDA filing · 2026
What to watchWatch for the specific PDUFA date announcement (Q1 2027) for the REZZAYO prophylaxis sNDA, which is the next major binary catalyst. The stock trades at ~$7.85 with ~$15.33 analyst target (95% upside) but carries ~20% short interest, suggesting a potential squeeze setup if the sNDA is approved. Monitor Q3 earnings on Nov 11, 2026 for REZZAYO revenue trajectory in the currently approved indications.
Price Chart
Executive Summary
CorMedix reported Q2 2026 consolidated revenue of $101.9M and net income of $26.0M ($0.33 basic EPS), compared to $39.7M revenue and $19.8M net income in Q2 2025. The company maintained full-year revenue guidance of $325-$345M and raised adjusted EBITDA guidance to $125-$140M. DefenCath sales of $66.1M and Melinta portfolio contributions of $35.8M drove results, while the company signed a new supply agreement with a large dialysis operator covering all top 5 U.S. providers.
Key Financial Metrics
Key Facts
- Q2 2026 consolidated revenue of $101.9M vs $39.7M in Q2 2025
- Net income of $26.0M ($0.33 basic EPS) vs $19.8M ($0.29 basic EPS) in Q2 2025
- Adjusted EBITDA of $58.7M vs $22.4M in Q2 2025
- Full-year 2026 revenue guidance maintained at $325-$345M
- Full-year adjusted EBITDA guidance raised to $125-$140M from $115-$135M
- DefenCath sales of $66.1M; Melinta portfolio contributed $35.8M
- New multi-year commercial supply agreement with a Large Dialysis Operator covering all top 5 U.S. providers
- Cash and short-term investments of $256.7M at June 30, 2026
- FDA submission of REZZAYO sNDA for prophylaxis expected in Q3 2026
Financial Impact
Revenue grew 156% YoY to $101.9M; net income increased 31% to $26.0M; adjusted EBITDA rose 162% to $58.7M
Risk Factors
- Sequential revenue decline from $127.4M in Q1 to $101.9M in Q2
- Pending TDAPA reimbursement expiration for DefenCath
- Ongoing securities litigation with $4.2M insurance reimbursement partially offsetting G&A
- Dependence on Melinta acquisition integration and pipeline execution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001410098-26-000054 |
| Document: crmd-20260813.htm | 0001410098-26-000054 |
| Document: 0001410098-26-000054-index-headers.html | 0001410098-26-000054 |
| Document: 0001410098-26-000054-index.html | 0001410098-26-000054 |
| Document: 0001410098-26-000054.txt | 0001410098-26-000054 |
| 8-K Data (Synthetic) | 0001410098-26-000054 |
Track record
21 reports on CRMD
9 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +34.13% at T+60 after the Mar 5, 2026 report. 10 of 12 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Bearish 5/10 Entry $4.84 Now $4.82 +0.41% settles Nov 19
- Nov 10, 20266d ago DEFA14A Neutral 6/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
- Nov 10, 20266d ago 8-K Bullish 7/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
- Nov 9, 20267d ago DEFA14A Neutral 6/10 Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
- Nov 9, 20267d ago 8-K Neutral 6/10 Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
- Nov 2, 202614d ago 8-K Neutral 5/10 No price data
- Nov 2, 202614d ago Press Release Neutral 4/10 Entry $5.39 to $5.47 Now $4.82 −10.58% ▲ +1.48% +1.41% vs SPY
- Oct 19, 202628d ago 8-K Bullish 7/10 Entry $7.38 to $7.94 Now $4.82 −34.69% ▲ +7.59% +7.73% vs SPY
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $7.38 to $8.03 Now $4.82 −34.69% ▲ +8.74% +8.88% vs SPY
- Aug 13, 202613w ago 8-K Neutral 5/10 Viewing No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers